Mesenchymal stem cell therapy for long COVID patients
Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients
This study is testing if umbilical cord stem cell therapy can help people with long COVID feel better by reducing symptoms like fatigue and breathing problems.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 76 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06492798 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness and safety of umbilical cord mesenchymal stem cell therapy in patients suffering from long COVID. Participants will receive either an intravenous infusion of mesenchymal stem cells or a placebo, with their symptoms assessed at various intervals throughout the study. The trial aims to determine if this therapy can alleviate long-term complications associated with COVID-19, such as fatigue and difficulty breathing. Data on participants' demographics, vital signs, and physical examinations will be collected to assess the therapy's impact.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with long COVID who meet the WHO criteria and are experiencing ongoing symptoms.
Not a fit: Patients with active malignant tumors, infections, or significant organ dysfunction may not benefit from this therapy.
Why it matters
Potential benefit: If successful, this therapy could significantly improve the quality of life for long COVID patients by alleviating persistent symptoms.
How similar studies have performed: While the use of stem cell therapy for various conditions has shown promise, this specific application for long COVID is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meeting the diagnostic criteria for Long COVID according to WHO. * Main symptoms assessed based on CTCAE 5.0. * Symptoms evaluated for exclusion reasons of other diseases by relevant specialists. * No recent plans for pregnancy (negative pregnancy test within 72 hours for women of childbearing age prior to the start of the trial), and willing to use effective non-pharmaceutical contraceptive measures during the study. * Signed informed consent forms and agreements to participate in this clinical trial. Exclusion Criteria: * Active malignant tumors. * Active infections. * Abnormal liver or kidney function (ALT, AST \> 2 times the upper limit of normal; Cr \> 2 times the upper limit of normal). * Women who are pregnant, lactating, or planning to become pregnant during the trial. * Participated in other clinical trials within the last 3 months prior to screening. * Other reasons deemed inappropriate for participation by the investigator.
Where this trial is running
Shanghai
- Shanghai Changhai Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Yuchao Dong, Doctor
- Email: dongyc1020@aliyun.com
- Phone: +86 021-31161314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.